SalvOvar Trial Featured at ASCO 2025: International Interest Grows
We're excited to share that the SalvOvar clinical trial was showcased at the 2025 ASCO Annual Meeting in Chicago, with a poster presentation by Prof. Benoit You in the "Trial in Progress" section.
The poster introduced the SalvOvar trial’s design and objectives, aimed at improving outcomes for patients with poor prognostic ovarian cancer. This includes those presenting with two key high-risk features:
- Unfavorable KELIM score (< 1.0)
- Disease not amenable to complete interval debulking surgery (IDS) after 3–4 cycles of neoadjuvant chemotherapy (NACT)
These patients often have limited response to standard treatments. SalvOvar investigates a more intensive approach: the SALV regimen, which delivers chemotherapy weekly at adjusted doses to enhance chemosensitization and personalize care.
The concept has already drawn international attention, with several countries expressing interest in joining the trial. While enrollment remains limited to current sites for now, the growing enthusiasm is encouraging—and we’ll share any future updates on trial expansion.
“Patients with poor-prognosis ovarian cancer urgently need tailored strategies,” said Prof. Benoit You, principal investigator of the SalvOvar trial. “With SalvOvar, we aim to personalize chemotherapy intensity based on the high-risk factors. The international interest we’ve received reflects a shared commitment to improving outcomes for this underserved population.”
This phase III study represents a hopeful direction for patients typically underserved by current therapeutic options.
A heartfelt thank you to all the participating patients, research teams, and collaborators making this trial possible.
Need to assess a patient’s KELIM score? Visit: biomarker-kinetics.org
